Open access
Open access
Powered by Google Translator Translator

RCT: Rituximab vs. tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis

7 Mar, 2021 | 19:06h | UTC

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial – The Lancet

Commentary: Precision medicine in rheumatology: are we getting closer? – The Lancet

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.